A Well-Balanced Pipeline
Boehringer Ingelheim has a rich pipeline showing a number of new molecular entities and a high share of products in late phase development. The company has brought a range of products from its own research & development to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US dollars or have blockbuster potential.
Compound* Clinical
phase
Indication
Therapeutic
principle
Mode of action
Empagliflozin** Submitted Diabetes
mellitus type II SGLT2-inhibition Inhibition of sodium
dependent glucose
transporter2
Empagliflozin+ Linagliptin** Phase III Diabetes mellitus
type II
SGLT2-inhibition
+ DPP-4 inhibition
Inhibition of glucose
transporter-2 +
Inhibition of
dipeptidyl peptidase 4
Empagliflozin+ Metformin** Phase III Diabetes mellitus
type II
SGLT2-inhibition+
biguanide
Inhibition of glucose
transporter-2 +
biguanide
New Insulin Glargine** Submitted Diabetes mellitus
type I + II
Insulin analogue Insulin analogue
Nintedanib Submitted
in EU Non-small cell lung
cancer (NSCLC)
Angiogenesis
inhibition
Triple angiokinase
inhibitor,
simultaneously blocks
VEGFR, FGFR,
PDGFR
Dabigatran etexilate Submitted Acute treatment and
prevention of
recurrent deep vein
thrombosis (DVT)
and pulmonary
embolism (PE)
Oral anticoagulation Direct reversible
thrombin inhibitor
(DTI)
Olodaterol Submitted/
Approved Chronic obstructive
pulmonary Disease
Anti-beta inhibition Long acting
beta agonist
(EMA as
Striverdi®)
(COPD) (LABA)
Tiotropium Submitted Asthma Bronchodilatation Long Acting
Muscarinic
Antagonist
(LAMA)
Afatinib Phase III Head and neck
cancer Signal transduction
inhibition
Novel
irreversible
ErbB Family
blocker
Nintedanib Phase III Ovarian cancer Angiogenesis
inhibition Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR
Nintedanib Phase III Idiopathic
pulmonary fibrosis
(IPF) Anti-fibrotic kinase
inhibition
Anti-fibrotic
kinase inhibitor
Tiotropium+Olodaterol Phase III Chronic obstructive
pulmonary
Disease(COPD) Antimuscarinic
inhibition/Anti-beta
inhibition
Long acting
muscarinic
agonist
(LAMA)+Long
acting beta
agonist
(LABA)
Volasertib Phase III Acute Myeloid
Leukemia (AML) Cell-cycle kinase
inhibition
PLK-1
antagonist
* These are investigational agents; their safety and efficacy have not yet been established. ** In collaboration with Eli Lilly and Company
Status: February 2014
Product name First
launch
Active ingredient Indication
Striverdi® 2014 Olodaterol Chronic obstructive pulmonary Disease
(COPD)
Giotrif® / Gilotrif™2013 Afatinib Non-small cell lung cancer (NSCLC) Jentadueto® 2012 Linagliptin+Metformin Diabetes mellitus type II
Trajenta® 2011 Linagliptin Diabetes mellitus type II
Pradaxa® 2010 Dabigatran etexilate Stroke prevention in atrial fibrillation Twynsta® 2010 Telmisartan+Amlodipine Essential hypertension
Pradaxa® 2008 Dabigatran etexilate Prevention of venous thromboembolic
events (VTE) in adults
Spiriva®
Respimat Soft Mist™
Inhaler
Spiriva®
2007
2002
Tiotropium COPD
Micardis® 1998 Telmisartan Essential hypertension
Sifrol® / Mirapex® /
Mirapexin®
2006
1997 Pramipexole Restless legs syndrome (RLS)
Parkinson's disease (PD)
Viramune® 1996 Nevirapine HIV/AIDS。